Trehalose and Alzheimer disease

Phase 2

Conditions: Alzheimer disease.
Dementia in Alzheimer's disease, atypical or mixed type
G30. 9

Registration Number: IRCT20130829014521N15

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 10

Inclusion Criteria

Mini-Mental State Examination (MMSE) score range from 10 to 23
Not having other cognitive disorders

Exclusion Criteria

MMSE score higher than 23 or lower than 10
The presence of other cognitive disorders which will be evaluated by clinical assessment and brain imaging
Vascular dementia and Lewy body dementia
Previous history of head trauma
Use of alcohol and other drugs that affect cognitive functioning

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in CDR-SB and MMSE scores. Timepoint: At the beginning and end of the intervention trial (Day 0 and week 12). Method of measurement: Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE) questionnaire.

Secondary Outcome Measures

Name	Time	Method
Alterations in Alzheimer disease-related microRNA levels. Timepoint: Baseline and week 12. Method of measurement: Real-time quantitative PCR.;Alteration in serum levels of phosphorylated tau protein. Timepoint: Baseline and week 12. Method of measurement: ELISA.;Alteration in serum levels of Aß42. Timepoint: Baseline and week 12. Method of measurement: ELISA.